Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Fig. 4

mTOR inhibitors (rapamycin, PP242) decreased the expressions of LDH-A and glutaminase proteins in HT-1080 cells; and glutaminase inhibitors (Zaprinast, BPTES) have effects on both the proliferation and the 2-HG oncometabolite level in these cells. LDH-A and Gls expressions were significantly reduced after 48 h rapamycin (50 ng/ml) and PP242 (1 μM) treatment (a. and b. show flow cytometric results, X-Gmean average ± SD n = 3,*:p < 0.05; c. Western blot). The effects of mTOR and glutaminase inhibitors on the 2-HG production and proliferation (d.) (Alamar Blue test; Rapa.: rapamycin 50 ng/mL; PP242: 1 μM; Zap.: Zaprinast 100 μM; BPTES: 10 μM). The effect of rapamycin and Zaprinast on the 2-HG production (e.) (LC-MS using U-13C-glutamine labelling; n = 3, levels of metabolites were expressed relative to the control (control level = 1), m + 0 = unlabelled 2-HG; m + 5 = 5 13C in 2-HG, n.d.: not detected; *:p < 0.05). The results of Alamar Blue test after using 48-h Zaprinast and rapamycin (50 ng/ml) combination treatments in HT-1080 cells (f.)

Back to article page